BOARD OF DIRECTORS


Dr. H. Sudarshan Ballal - Manipal Health Enterprise, Bangalore
Medical Director & Chairman of Medical Advisory Board, Manipal Health Enterprises Pvt. Ltd

Dr. H.Sudarshan Ballal was the best outgoing student (Blue Ribbon awardee) of the Kasturba Medical College, Manipal and a recipient of many Gold Medals in MBBS and M.D. He had his further training in the USA and had the distinction of being one of the few to be triple Board certified in Internal Medicine, Nephrology & Critical Care. He has the rare distinction of being appointed as Professor of Medicine with St. Louis University School of Medicine (USA) and is also Adjunct Professor of Medicine at Manipal University. He was conferred the fellowship of the Royal College of Physicians, London for his contribution in Medicine. After working as a Consultant in Nephrology and Transplantation at the St. Louis University School of Medicine, he moved back to India to head the Nephrology Unit at Manipal Hospital, Bangalore. He has been with Manipal Hospital, Bangalore ever since its inception and is currently holds the position of Chairman, Manipal Health Enterprises Pvt. Ltd., and the Director of Manipal Institute of Nephrology & Urology. He is also a member of the Board of Manipal Health Enterprises Pvt. Ltd. A clinician par excellence, excellent teacher and a compassionate physician, he had set up the first postgraduate training Centre in Nephrology in Karnataka and performed the first cadaver kidney transplantation in Karnataka. He was awarded the prestigious Rajyothsava Award by the Government of Karnataka in 2005 for his contributions in the field of Medicine. He also has been bestowed with the prestigious Namma Bengaluru Awards 2009 for his Individual achievements. He was conferred with the prestigious doctors' award in memory of Dr. B. C. Roy by the government of Karnataka in 2010. Further, he was conferred with the Trinity Vaidya Rathna Award 2010 for the yeoman service to mankind by Trinity Health and Educational Trust. And also he was recognized for Sagar Awards 2010 and Aryabhata International Award in 2011 for his excellent service and contribution in the field of medicine. He has also been nominated as a Member of the Senate of Rajiv Gandhi University of Health Sciences and is a member of the senate of Manipal University, Karnataka.

 

Mr. Chandru has 28 years of experience in leading and managing bio pharmaceutical businesses across diverse geographies and segments. He has a proven track record having managed

P&Ls and Strategy and Business Development globally. His varied experience straddles start-ups, acquired companies and multiple product segments. In his last role as Senior Vice President – International for Lupin, he headed business operations spread across emerging markets in Asia, Latin America and Africa with directorial responsibility in multiple subsidiaries. Prior to this, Chandru has worked with Wockhardt as General Manager for emerging markets. At Cipla, he has played a leadership role in its transformation from a "partner led" business model to a business that stands on innovation and meaningful commercial presence in key markets driving initiatives across emerging markets, biotechnology, US specialty and consumer health. Chandru championed the creation of a business and innovation incubator called Cipla New Ventures (CNV), where it is nurturing in venture style, businesses that require unique entrepreneurial and start up like eco systems. This included investments in Consumer health, regenerative medicine, drug repurposing and Bio-similar drugs. Cipla Health was recently spun out as a FMCG style consumer health company with a Series A investment from a marquee investor, Fidelity. Its investments in Chase Pharma, an Alzheimer's company, saw a successful exit.

Mr. B. N. Manohar - MD & CEO, Stempeutics Research

Manohar has been associated with the Manipal Education & Medical Group (MEMG) for the last 14 years and has taken up the role of CEO at Stempeutics in August 2007. He is responsible for making Stempeutics a leading stem cell company in Asia. He is responsible for developing innovative stem cell products addressing major unmet medical needs with an India first global next approach. His responsibilities include implementing strategies which will shape future business delivery and contribute to the achievement of the Company's objectives both strategic and financial. Under his leadership Stempeutics has crossed various milestones including successful conduct of Phase 2 clinical trials in India and Malaysia, obtaining ATMP & ODD classification in Europe, getting patents from USA, Japan, ANZ and China. Prior to this assignment, Manohar has handled multiple assignments in the MEMG – starting Manipal Infocom a BPO Organization and successfully migrating it to Manipal–Omega Healthcare BPO JV, taking over a startup Distance Education business and growing it to US$ 18M, establishing and propping up the new Education Services business. Prior to Joining Manipal Group, Manohar has had 12 years successful stints at Wipro GE Medical Systems. At GE Medical he has handled multiple senior assignments including Vice President – Customer Service and as Chief Operating Officer of IT Joint Venture - GE Medical Systems Information Technology, at Hyderabad. Manohar has done his B.E. from Regional Engineering College, Trichy and M.E. from Guindy Engineering College, Chennai.

Dr Jaideep Gogtay – Global Chief Medical Officer, Cipla Ltd

Dr Jaideep A Gogtay is the Global Chief Medical Officer at Cipla and has been associated with the organization for nearly 25 years now. Jaideep completed his medical graduation (M.B.B.S) from Grant Medical College and Sir J J Group of Hospitals in Mumbai. He then received his M.D degree in Pharmacology from Seth GS Medical College and KEM Hospital. During his post-graduation, he worked as a lecturer of Pharmacology. At Cipla, he has been closely involved in the development and introduction of several drugs in various therapeutic fields, particularly in HIV/AIDS, infectious diseases and respiratory diseases. He has worked on several clinical trials in the field of asthma, COPD and infectious diseases. He was a key member of the team which introduced several antiretroviral drugs for the treatment of AIDS including the 1$ a day triple drug cocktail. Cipla has a large number of anti-infective drugs including antibiotics, anti-viral and anti-fungal which are available in a number of countries. As head of medical affairs, he was responsible for bringing back ‘old’ antibiotics such as Colistin which was reintroduced in India after over 50 years. One of the areas that Cipla continues to work is to update physicians on appropriate use of antibiotics and the current challenges of antimicrobial resistance, both in the community and in the hospital. He was a member of the Association of Physicians of India (Guidelines 2005) on ‘Antiretroviral therapy’. He has 40 publications to his credit including chapters on Pharmacokinetics and Pharmacodynamics of antibiotics and has presented papers at over 50 conferences. He was involved in setting up the Chest Research Foundation (CRF), now an independent research center dedicated to research in the field of respiratory medicine. He is a frequent presence in workshops on research methodology at academic institutions and at several national and international forums.

Dr Ramkumar Mandalam – President & CEO, Cellerant Therapeutics, USA

Ramkumar (Ram) Mandalam has served as the President & CEO and a Board Member and of Cellerant Therapeutics since 2008. Under his leadership, Cellerant has rapidly expanded from an early-stage to an advanced clinical-stage company developing a pipeline of candidates for treatment of heamatological malignancies. Prior to Cellerant, Dr. Mandalam led the development and manufacturing of cell-based therapies for treatment of degenerative diseases and cancer at Geron Corporation. Previously, he was Director of Developmental Research at Aastrom Biosciences, where he was responsible for the research and development programs involving ex vivo expansion of human bone marrow stem cells and dendritic cells. He currently serves on the board of Cryoport, Inc. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. Dr. Mandalam is the author or co-author of several publications, patent applications, and abstracts.

Mr. Anurag Bagaria – Chairman & CEO, Kemwell Biopharma

Anurag Bagaria is responsible for managing and driving Kemwell’s performance, formulating and executing long-term strategies, and leading the company’s business operations globally. He is committed to developing strong customer relationships, with a passion for building Kemwell’s delivery capabilities, and a disciplined focus on operations and execution. Anurag joined Kemwell in 2004 as a second-generation entrepreneur and became Chairman in 2010. He holds a degree in Chemical Engineering from Cornell University and an MBA from Kellogg in the US.



SCIENTIFIC ADVISORY BOARD



Dr. Mahendra Rao – Ex Director – NIH, USA

Dr. Rao is internationally renowned for his research in stem cells and regenerative medicine. He has worked in the stem cell field for more than 2 decades, with positions in academia, government, regulatory affairs and industry, and he has authored more than 300 publications. He received his M.D. from Bombay University and his Ph.D. in developmental neurobiology from the California Institute of Technology. Following postdoctoral training at Case Western Reserve University, he established his research laboratory in neural development at the University of Utah. He next joined the National Institute on Aging as Chief of the Neurosciences Section where he studied neural progenitor cells. In 2011, Rao was appointed Director of the National Institutes of Health, Centre for Regenerative Medicine. Before that he was Vice President of Regenerative Medicine at Life Technologies. He has also participated on committees including Chairman of the U.S. Food and Drug Administration's Cellular Tissue and Gene Therapies Advisory Committee, the California Institute of Regenerative Medicine, International Society for Stem Cell Research and as the liaison to the International Society for Cellular Therapy .

Dr. Jeff Karp - Professor, Harvard Medical School, Boston, USA

Dr. Jeff Karp is a Professor at Brigham and Women's Hospital, Harvard Medical School, and is Principal Faculty at the Harvard Stem Cell Institute and affiliate faculty at MIT through the Harvard-MIT Division of Health Sciences and Technology. His research harnesses materials science and stem cell biology to solve medical problems with emphasis on nanoscale/microscale materials and bio-inspired approaches. He has published more than 100 peer-reviewed papers and book chapters and has given over 140 national and international invited lectures and has 50 issued or pending patents. Several technologies that Dr. Karp has developed have formed the foundation for multiple products under development and for the launch of two companies, Gecko Biomedical and Skintifique. Dr. Karp's work has been recognized by CNN, NPR Science Fridays, Boston Globe, ABC News, MSNBC, Fox News, CBC Quirks and Quarks, CanadaAM, BBC, LA Times, Forbes, National Geographic, Popular Science, the Washington Post, the New York Post, and by Wired Magazine. In 2011 the Boston Business Journal recognized Dr. Karp as a Champion in Healthcare Innovation and in 2013 the Institute for Chemical Engineers (IChemE) awarded one of his technologies at the Most Innovative Product of the Year. MIT's Technology Review Magazine (TR35) also recognized Dr. Karp as being one of the top innovators in the world under the age of 35.

Prof. Polani B Seshagiri – IISc, Bangalore

Prof. Polani Seshagiri, PhD is a Professor at MRDG (Molecular Reproduction, Development and Genetics), Indian Institute of Science Bangalore, India. He completed PhD from Indian Institute of Science and Post-doctoral training at Dept. of Vet. Sci., Univ. of WI, Madison, USA. Subsequently he joined as faculty at Primate Research Centre, Univ. of WI, Madison, USA as Assistant Scientist. Later he joined as faculty MRDG (Molecular Reproduction, Development and Genetics), Indian Institute of Science Bangalore, India. His research interest is in studying early mammalian development with regard to the acquisition of fertilizing potential of spermatozoa and development of embryos through peri-implantation stages with particular reference to the phenomenon of blastocyst hatching. Besides, his lab is studying on cell lineage specification by using ES-cells as model system. He has been involved in stem cell research for more than a decade. He has co-authored more than 100 primary article, reviews, and editorials on different aspects of development biology and stem cell biology. He is an expert in developmental biology and for the last 20 years has acted as a scientific consultant for a broad range of constituencies in academia, government, regulatory affairs and industry.

Dr. Urmila Thatte – Professor & Head, Dept. of Clinical Pharmacology, KEM Hospital, Mumbai

Dr. Urmila Thatte started her career in pharmacology at the Seth GS Medical College and KEM Hospital. After almost twenty years of hard work and dedication to her subject in the department, Thatte got an opportunity to develop clinical pharmacology at Nair Hospital. She has been working in this department for the last six years. She is working with almost all governmental organizations in various capacities i.e. member of advisory committees or task force. A popular figure amongst the pharmacology fraternity, Thatte carries many stars to her credit. She serves on the National Pharmacovigilance Advisory Committee and is also the Coordinator of the Regional Pharmacovigilance Centre of the National Pharmacovigilance Programme. She is also on the WHO Expert Advisory Panel on Drug Evaluation. Her main areas of research interest include rational use of drugs in developing countries, herbal medicine and conceptual understanding of Ayurveda. She also serves on the ethics committees of the Tata Memorial Hospital, Hinduja Hospital and KEM Hospital as well as on the Independent Ethics Committee, Mumbai. She is also the Secretary of the Forum for Ethics Review Committees in India

Dr. Anish Sen Majumdar, PhD - Ex Chief Scientific Officer & Executive Vice President

Dr. Anish Sen Majumdar is an internationally renowned scientist having rich experience in research and development in stem cells. Dr. Anish received Ph.D. in Biochemistry from the University of Calcutta. He pursued postdoctoral research in the University of Pennsylvania, Philadelphia and Stanford University Medical School. He has worked as a Staff Scientist in Becton Dickinson systems, SanJose and in Geneic Sciences, Menlo Park and as a Senior Research Scientist and later as Project Manager, in Aventis Gencell Hayward, California. Dr. Anish joined Geron Corporation USA in 1998 as a Senior Staff Scientist and became Senior Director of Cell Therapy Research in 2005. He has led several research groups: Pancreatic differentiation from human ES cells for Diabetes; Telomerase based dendritic cell vaccine for cancer; ES cell derived oligodendrocytes for spinal cord injury. After Geron, Dr. Anish joined Reliance Life Science as Vice President, Stem Cell Research in Regenerative Medicine. He was responsible for developing and directing Research and Development activities in the areas of both embryonic and adult stem cells. Dr. Anish has published more than 45 scientific research articles in internationally acclaimed journals and as coauthored in more than 10 patents